Cardiff Oncology, Inc.

NASDAQ:CRDF

Biotechnology

Healthcare
$0.84 +2.12%

+$0.03 today

Market cap
$65.27M
Beta
1.38
P/E (TTM)
-1.8
EPS (TTM)
-$0.65
52W Low $1.16High $4.56

Volume 0.86M

Average 1.05M

CRDF Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Cardiff Oncology, Inc.NASDAQ: CRDF

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation grows in line with its trailing trend

Q1 FY2026 stock-based compensation of $1.66M rose 21.6% year over year, ahead of the +19.7% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 31.6% from the prior quarter. Over 3 fiscal years it compounded at +10.2% a year.

Context

  • Stock-based compensation amounted to 960.0% of revenue in FY2025, up 263.1 pp from a year earlier.
  • Stock-based compensation increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +21.6% holds above the trailing-twelve-month pace of +19.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.66M+31.6% QoQ
Last fiscal yearDec 2025
$5.69M+19.6% YoY
LTMMar 2026
$5.99M+19.7% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+21.6%——
1 year+19.6%——
3-year CAGR+10.2%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
5.69M USD
Year-over-year change
+19.6%
4-year CAGR
+15.2%

Stock-Based Compensation vs competitors

How CRDF compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +19.7% is the 3rd highest of 9, against a peer median of +1.9%.
  • Stock-based compensation amounts to 1140.6% of revenue for CRDF, versus a peer median of 210.3%.
CRDF Competitors
Stock-Based Compensation for CRDF and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PEPGPepGen Inc.LTM Mar 2026$10.03M USD-22.0%+30.6%—
FBRXForte Biosciences, Inc.LTM Mar 2026$7.82M USD+99.9%+15.9%—
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$6.67M USD-45.2%-9.2%210.3%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$6.49M USD-5.6%+3.2%—
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$6.14M USD+9.4%-6.2%344.3%
CRDFCardiff Oncology, Inc.LTM Mar 2026$5.99M USD+19.7%+10.2%1140.6%
IPHAInnate Pharma S.A.FY2025€4.26M EUR+7.9%+0.1%152.7%
MOLNMolecular Partners AGLTM Mar 2026CHF 4.21M CHF-4.1%-4.6%—
ELTXElicio Therapeutics, Inc.LTM Mar 2026$3.05M USD+83.8%+67.0%—
Peer median (excluding CRDF) —+1.9%+1.6%210.3%

Competitors are the stored peer set for CRDF. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(28.29M)(38.7M)(41.44M)(45.43M)(45.85M)
Depreciation & Amortization451K236K398K404K904K
Deferred Income Tax1.32M0000
Stock-Based Compensation3.23M4.26M4.51M4.76M5.69M
Change in Working Capital(1.79M)(380K)6.57M3.17M2.18M
Accounts Receivables(215K)(236K)483K(484K)591K
Inventory00000
Accounts Payables719K1.35M2.83M2.99M2.2M
Other Working Capital(2.29M)(1.49M)3.25M671K(614K)
Other Non-Cash Items2.03M772K(921K)(598K)(848K)
Operating Cash Flow(23.04M)(33.82M)(30.89M)(37.69M)(37.92M)
Capital Expenditures(205K)(892K)(582K)(80K)(44K)
Acquisitions (Net)205K(114K)000
Purchases of Investments(174.39M)(91.23M)(70.08M)(23.56M)(71.12M)
Sales of Investments43.14M130.27M106.86M37.37M73.25M
Other Investing Activities(205K)114K00(744K)
Investing Cash Flow(131.45M)38.15M36.2M13.73M1.34M
Debt Repayment00000
Common Stock Issued34.19M75K053.41M2.58M
Common Stock Repurchased00000
Dividends Paid(24K)(414K)000
Other Financing Activities1.29M414K0373K0
Financing Cash Flow35.45M75K053.78M2.58M
Effect of Forex Changes00000
Net Change in Cash(119.04M)4.4M5.31M29.82M(34M)
Free Cash Flow(23.25M)(34.71M)(31.47M)(37.77M)(37.97M)

Cardiff Oncology, Inc.

NASDAQ:CRDF

Intrinsic Alpha fair value

Locked

Current Price

$0.84

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.